- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00282243
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Palo Alto, California, Estados Unidos
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80262
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
-
Rochester, Minnesota, Estados Unidos, 55905
-
-
New York
-
New York, New York, Estados Unidos, 10029
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient is currently receiving Prograf ® based immunosuppressive therapy for liver transplantation.
- Patient has stable whole blood trough level concentrations of Prograf® and is clinically stable
Exclusion Criteria:
- Patient has previously received an organ transplant other than a liver
- Patient is currently receiving sirolimus immunosuppression therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Tacrolimus MR
After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study. Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons. |
Oral
Otros nombres:
Oral
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus
Periodo de tiempo: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
The area under the concentration-time curve was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state using the linear trapezoidal rule.
The AUC0-24 for tacrolimus was calculated as the sum of the AUC0-12 for the morning (0-12 hour) and afternoon (12-24 hour) doses.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Minimum Observed Concentration of Tacrolimus (Cmin)
Periodo de tiempo: Days 14 and 42 at 12 hours post-dose (tacrolimus) and Days 28 and 56 at 24 hours post-dose (for tacrolimus MR).
|
The trough (minimum) concentration of tacrolimus determined from the tacrolimus whole blood concentration value at the 12 hour post-dose concentration based on the evening dose (i.e., the 8 am concentration) for tacrolimus and the 24-hour time point post-dose for tacrolimus MR, prior to receiving the next dose.
|
Days 14 and 42 at 12 hours post-dose (tacrolimus) and Days 28 and 56 at 24 hours post-dose (for tacrolimus MR).
|
Patient Survival
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
Patient survival was defined as any participant known to be alive at the time of analysis.
|
From enrollment until the end of study (up to 60 months).
|
Graft Survival
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
Graft survival was defined as any participant who did not meet the definition of graft loss, where graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Número de participantes con múltiples episodios de rechazo
Periodo de tiempo: Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Este análisis incluye episodios de rechazo que fueron confirmados por biopsia por el patólogo del sitio clínico o tratados clínicamente.
|
Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Número de participantes con episodios de rechazo agudo tratados clínicamente
Periodo de tiempo: Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Un episodio de rechazo agudo tratado clínicamente fue cualquier episodio de rechazo confirmado o sospechado por biopsia que se trató con terapia inmunosupresora.
|
Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Número de participantes con rechazo crónico
Periodo de tiempo: Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Debido al bajo número de participantes con episodios de rechazo agudo confirmados por biopsia, no se analizó el rechazo crónico.
|
Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Número de participantes con fracaso del tratamiento
Periodo de tiempo: Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
El fracaso del tratamiento se definió como la interrupción del fármaco del estudio por cualquier motivo.
Debido a la interrupción del estudio por parte del patrocinador, no se analizó el fracaso del tratamiento.
|
Desde la inscripción hasta el final del estudio (hasta 60 meses).
|
Maximum Observed Concentration of Tacrolimus (Cmax)
Periodo de tiempo: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
The maximum concentration was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state, without interpolation.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Time to Maximum Observed Concentration of Tacrolimus (Tmax)
Periodo de tiempo: Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Time to the first occurrence to reach the maximum concentration of tacrolimus was calculated from whole blood tacrolimus concentrations for both the tacrolimus and tacrolimus MR treatment periods at steady state, without interpolation.
|
Days 14 and 42 (tacrolimus) and Days 28 and 56 (tacrolimus MR), pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (pre-dose for tacrolimus only), 12.5, 13, 14, 15, 16, 18, 20, and 24 hours post-dose.
|
Percentage of Participants With Biopsy-confirmed Acute Rejection
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
Biopsy-confirmed acute rejection (BCAR) is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the pathologist at the clinical site according to the 1997 Banff criteria for grading of acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I (Mild): Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II (Moderate): Rejection infiltrate, expanding to most or all of the triads; Grade III (Severe): Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
|
From enrollment until the end of study (up to 60 months).
|
Time to Event for Patient Non-survival
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
For participants who died on study, the median number of days from first dose of study drug to death due to any cause.
|
From enrollment until the end of study (up to 60 months).
|
Time to Event for Graft Non-survival
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
For participants with graft loss, the median number of days from the first dose of study drug to graft loss.
Graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Time to First Biopsy-confirmed Acute Rejection
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
For participants with a biopsy-confirmed acute rejection (BCAR), the median number of days from the first dose of study drug to the date of biopsy confirmation.
BCAR is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the clinical site pathologist according to the 1997 Banff criteria for grading acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I: Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II: Rejection infiltrate, expanding to most or all of the triads; Grade III: Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
|
From enrollment until the end of study (up to 60 months).
|
Grade of Biopsy-confirmed Acute Rejection Episodes
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
Biopsy-confirmed acute rejection (BCAR) is defined as an episode of acute liver allograft rejection that was confirmed by biopsy results and was Banff grade ≥ I. Biopsies were graded by the clinical site pathologist according to the 1997 Banff criteria for grading of acute liver allograft rejection: Indeterminate: Portal inflammatory infiltrate that fails to meet the criteria for diagnosis of acute rejection; Grade I (Mild): Rejection infiltrate in a minority of the triads that is generally mild and confined within the portal spaces; Grade II (Moderate): Rejection infiltrate, expanding to most or all of the triads; Grade III (Severe): Rejection infiltrate, expanding to most or all of the triads, with spillover into periportal areas and moderate to severe perivenular inflammation that extends into the hepatic parenchyma and is associated with perivenular hepatocyte necrosis.
For participants with more than one biopsy-confirmed acute rejection episode, the worst case grade is reported.
|
From enrollment until the end of study (up to 60 months).
|
Number of Participants Receiving Anti-lymphocyte Antibody Therapy for Acute Rejection
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
Steroid-resistant rejection episodes were treated with anti-lymphocyte antibodies.
If a participant had a histologically proven Banff Grade II or III rejection, they could be initiated on anti-lymphocyte antibody treatment per institutional practice.
|
From enrollment until the end of study (up to 60 months).
|
Primary Reason for Graft Loss
Periodo de tiempo: From enrollment until the end of study (up to 60 months).
|
The primary reason for graft loss was recorded by the Investigator.
Graft loss was defined as graft failure (re-transplant) or participant death.
|
From enrollment until the end of study (up to 60 months).
|
Change From Baseline in Alanine Aminotransferase (ALT)
Periodo de tiempo: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring alanine aminotransferase levels over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Change From Baseline in Aspartate Aminotransferase (AST)
Periodo de tiempo: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring aspartate aminotransferase levels over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Change From Baseline in Total Bilirubin
Periodo de tiempo: Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Hepatic function was assessed by measuring total bilirubin over the course of the study.
|
Baseline (the last day of tacrolimus on Day 14 prior to the first conversion to tacrolimus MR), Day 56 (end of the pharmacokinetic phase) and end of treatment (EOT; the last observed value during treatment, maximum time on study was 60 months).
|
Safety as Assessed by Adverse Events, Laboratory Parameters and Vital Signs
Periodo de tiempo: From the first dose of tacrolimus MR formulation through the last dose day plus 10 days (approximately 60 months).
|
An adverse event is defined as any reaction, side effect or other untoward medical occurrence, regardless of the relationship to study drug which occurred during the conduct of a clinical study. Clinically significant adverse changes in clinical status, routine laboratory studies or physical examinations were considered adverse events. A serious adverse event was any adverse event occurring at any dose that resulted in any of the following outcomes:
|
From the first dose of tacrolimus MR formulation through the last dose day plus 10 days (approximately 60 months).
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Central Contact, Astellas Pharma US, Inc.
Publicaciones y enlaces útiles
Publicaciones Generales
- Florman S, Alloway R, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27;83(12):1639-42. doi: 10.1097/01.tp.0000265445.09987.f1.
- Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Wisemandle K, Fitzsimmons W, First MR. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005 Mar;37(2):1211-3. doi: 10.1016/j.transproceed.2004.11.086.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 02-0-152
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre tacrolimus
-
Novartis PharmaceuticalsTerminadoReceptor de trasplante de hígadoBélgica, España, Alemania, Italia, Australia, Estados Unidos, Países Bajos, Irlanda, Suecia, Brasil, Colombia, Francia, Federación Rusa, Argentina, Chequia, Reino Unido
-
Novartis PharmaceuticalsTerminadoTrasplante de hígadoEstados Unidos, Bélgica, Colombia, España, Alemania, Italia, Australia, Israel, Francia, Hungría, Países Bajos, Argentina, Canadá, Irlanda, Suecia, Brasil, Reino Unido, Federación Rusa, República Checa
-
Heleen GrootjansChiesi Farmaceutici S.p.A.ReclutamientoTrasplante de pulmón; ComplicacionesPaíses Bajos
-
Taro Pharmaceuticals USATerminado
-
Astellas Pharma IncAstellas Pharma Korea, Inc.TerminadoTrasplante de hígadoCorea, república de
-
Limerick BioPharmaTerminado
-
Loyola UniversityVeloxis PharmaceuticalsReclutamientoEnfermedades Renales Crónicas | Transplante de corazónEstados Unidos
-
NovartisSandozTerminadoTrasplante RenalEstados Unidos
-
Philipps University Marburg Medical CenterActivo, no reclutandoTrasplante de pulmónAustria, Alemania
-
NURIA LLOBERAS BLANCHTerminadoTRASPLANTE DE RIÑÓNEspaña